Could postbiotics soothe diarrhea? small trial tests new supplement
NCT ID NCT06738420
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed pilot trial tested two postbiotic supplements (ABB S3 and ABB C22) in 100 hospitalized patients with diarrhea or gut symptoms from tube feeding. The goal was to see if these nutritional supplements could ease symptoms like diarrhea, vomiting, and improve stool consistency. Researchers measured gut inflammation markers and symptom changes, but as a small early study, results are preliminary.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- postbiotics (ABB S3 and ABB C22)
- What this could lead to
- If successful, this could point toward a simple nutritional supplement to ease diarrhea and gut discomfort in hospitalized patients.
- What could go wrong
- This is a small, early pilot trial with no phase, so results may not apply broadly. The supplements may not outperform a placebo in real-world settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
100 people
The number who actually took part.
- Started
-
Jan 2023
- Finished
-
Apr 2024
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Inpatients of the centre * Diagnostic of diarrhoea: increase in daily faecal weight \> 200 g (as per the Centre protocol). * Subjects who as per the Centre protocol require Oral rehydration therapy * Patients with the ability to take the study product orally Exclusion Criteria: * History of allergy, idiosyncrasy, hypersensitivity or adverse reactions to the active principle or to any of the excipients. * History or evidence of any medical conditions or medication used that, in the opinion of the principal investigator, could affect the safety of the subjects or interfere with the study evaluations * Patients in situation of last days * Amytriptilin and masalazine treatment (anti-depressives) * Laxatives
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Diarrhoea and gastrointestinal symptoms secondary to enteral nutrition are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Isabel Roig
Barcelona, Barcelona, 0803', Spain